Unveiling the non-canonical functions of EZH2 in prostate cancer

by Impact Journals LLCProstate cancer cells. Credit: NIH Image GalleryA new editorial paper was published inOncotargettitled "Unveiling the non-canonical functions of EZH2 in prostate

Updated on: December 26,2023

Unveiling the non-canonical functions of EZH2 in prostate cancer

by Impact Journals LLCProstate cancer cells. Credit: NIH Image GalleryA new editorial paper was published inOncotargettitled "Unveiling the non-canonical functions of EZH2 in prostate

Updated on:December 26,2023

A feasibility study for salvage radiation therapy in prostate cancer

by Impact Journals LLCCredit: CC0 Public DomainAn editorial paper waspublishedinOncoscienceon May 20, 2024, titled, "Deep learning-assisted lesion segmentation in PET/CT i

Updated on: July 08,2024

A feasibility study for salvage radiation therapy in prostate cancer

by Impact Journals LLCCredit: CC0 Public DomainAn editorial paper waspublishedinOncoscienceon May 20, 2024, titled, "Deep learning-assisted lesion segmentation in PET/CT i

Updated on:July 08,2024

FDA approves engineered cell therapy for treating rare sarcoma

by Julie Grisham,Memorial Sloan Kettering Cancer CenterCredit: CC0 Public DomainThe U.S. Food and Drug Administration (FDA) hasgranted accelerated approvalfor the immunotherapy afami

Updated on: August 27,2024

FDA approves engineered cell therapy for treating rare sarcoma

by Julie Grisham,Memorial Sloan Kettering Cancer CenterCredit: CC0 Public DomainThe U.S. Food and Drug Administration (FDA) hasgranted accelerated approvalfor the immunotherapy afami

Updated on:August 27,2024

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on: December 26,2023

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on:December 26,2023

Diagnosis of ovarian cancer delayed by woeful lack of awareness

by World Ovarian Cancer CoalitionA global study of women with ovarian cancer has found that two thirds of women had never heard of the disease, or did not know anything about it before their diagnosis

Updated on: December 18,2023

Diagnosis of ovarian cancer delayed by woeful lack of awareness

by World Ovarian Cancer CoalitionA global study of women with ovarian cancer has found that two thirds of women had never heard of the disease, or did not know anything about it before their diagnosis

Updated on:December 18,2023

Precision physical activity prescriptions improve survival in colon cancer

by Pennington Biomedical Research CenterCredit: Unsplash/CC0 Public DomainPhysical activity may be associated with improved outcomes for patients undergoing postoperative treatment for Stage III colon

Updated on: December 26,2023

Precision physical activity prescriptions improve survival in colon cancer

by Pennington Biomedical Research CenterCredit: Unsplash/CC0 Public DomainPhysical activity may be associated with improved outcomes for patients undergoing postoperative treatment for Stage III colon

Updated on:December 26,2023

SABCS: Long-term outcomes good for PBI in early breast cancer

(HealthDay)—For patients with early-stage breast cancer, 10-year outcomes are similar for treatment with partial breast irradiation (PBI) and whole breast irradiation (WBI), according to a study prese

Updated on: December 22,2023

SABCS: Long-term outcomes good for PBI in early breast cancer

(HealthDay)—For patients with early-stage breast cancer, 10-year outcomes are similar for treatment with partial breast irradiation (PBI) and whole breast irradiation (WBI), according to a study prese

Updated on:December 22,2023

Predicting prostate cancer recurrence 15 months sooner

by Steve Martin,Purdue UniversityGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.105430A Purdue University mechanical engineer and his international collaborators

Updated on: January 06,2024

Predicting prostate cancer recurrence 15 months sooner

by Steve Martin,Purdue UniversityGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.105430A Purdue University mechanical engineer and his international collaborators

Updated on:January 06,2024

New tool combines evolution and AI to predict prostate cancer recurrence more than a decade ahead

New tool combines evolution and AI to predict prostate cancer recurrence more than a decade aheadbyInstitute of Cancer ResearchStudy design. Credit:Nature Cancer(2024). DOI: 10.1038/

Updated on: July 17,2024

New tool combines evolution and AI to predict prostate cancer recurrence more than a decade ahead

New tool combines evolution and AI to predict prostate cancer recurrence more than a decade aheadbyInstitute of Cancer ResearchStudy design. Credit:Nature Cancer(2024). DOI: 10.1038/

Updated on:July 17,2024

Barriers to early clinical trial access for adolescents and young adults still exist

byEuropean Society for Medical OncologyYoung cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congre

Updated on: December 18,2023

Barriers to early clinical trial access for adolescents and young adults still exist

byEuropean Society for Medical OncologyYoung cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congre

Updated on:December 18,2023

Energy stress triggers PFKL-dependent lipid droplet-mitochondria tethering and β-oxidation to support tumor growth

Updated on: September 15,2024

Energy stress triggers PFKL-dependent lipid droplet-mitochondria tethering and β-oxidation to support tumor growth

Updated on:September 15,2024

Researchers develop treatment that turns tumors into cancer vaccine factories

by The Mount Sinai HospitalCredit: CC0 Public DomainResearchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach

Updated on: June 11,2024

Researchers develop treatment that turns tumors into cancer vaccine factories

by The Mount Sinai HospitalCredit: CC0 Public DomainResearchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach

Updated on:June 11,2024